Logo image of PMCB

PHARMACYTE BIOTECH INC (PMCB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PMCB - US71715X2036 - Common Stock

0.7736 USD
-0.05 (-6.07%)
Last: 11/28/2025, 7:55:18 PM
0.7777 USD
+0 (+0.53%)
After Hours: 11/28/2025, 7:55:18 PM
Fundamental Rating

3

Taking everything into account, PMCB scores 3 out of 10 in our fundamental rating. PMCB was compared to 533 industry peers in the Biotechnology industry. PMCB has a great financial health rating, but its profitability evaluates not so good. PMCB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PMCB had negative earnings in the past year.
PMCB had a negative operating cash flow in the past year.
PMCB had negative earnings in 4 of the past 5 years.
PMCB had a negative operating cash flow in each of the past 5 years.
PMCB Yearly Net Income VS EBIT VS OCF VS FCFPMCB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

1.2 Ratios

With an excellent Return On Assets value of -7.80%, PMCB belongs to the best of the industry, outperforming 85.96% of the companies in the same industry.
PMCB has a Return On Equity of -8.07%. This is amongst the best in the industry. PMCB outperforms 89.51% of its industry peers.
Industry RankSector Rank
ROA -7.8%
ROE -8.07%
ROIC N/A
ROA(3y)2.56%
ROA(5y)-9%
ROE(3y)-1.51%
ROE(5y)-12.48%
ROIC(3y)N/A
ROIC(5y)N/A
PMCB Yearly ROA, ROE, ROICPMCB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PMCB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMCB Yearly Profit, Operating, Gross MarginsPMCB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for PMCB has been reduced compared to 1 year ago.
The number of shares outstanding for PMCB has been increased compared to 5 years ago.
PMCB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PMCB Yearly Shares OutstandingPMCB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
PMCB Yearly Total Debt VS Total AssetsPMCB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

PMCB has an Altman-Z score of -0.63. This is a bad value and indicates that PMCB is not financially healthy and even has some risk of bankruptcy.
PMCB's Altman-Z score of -0.63 is in line compared to the rest of the industry. PMCB outperforms 56.55% of its industry peers.
PMCB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.63
ROIC/WACCN/A
WACCN/A
PMCB Yearly LT Debt VS Equity VS FCFPMCB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

2.3 Liquidity

PMCB has a Current Ratio of 18.01. This indicates that PMCB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PMCB (18.01) is better than 94.76% of its industry peers.
PMCB has a Quick Ratio of 18.01. This indicates that PMCB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 18.01, PMCB belongs to the best of the industry, outperforming 94.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.01
Quick Ratio 18.01
PMCB Yearly Current Assets VS Current LiabilitesPMCB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

PMCB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -152.25%.
EPS 1Y (TTM)-152.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMCB Yearly EPS VS EstimatesPMCB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2022 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PMCB. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMCB Price Earnings VS Forward Price EarningsPMCB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMCB Per share dataPMCB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMCB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMACYTE BIOTECH INC

NASDAQ:PMCB (11/28/2025, 7:55:18 PM)

After market: 0.7777 +0 (+0.53%)

0.7736

-0.05 (-6.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-15 2025-09-15/amc
Earnings (Next)12-11 2025-12-11
Inst Owners1.24%
Inst Owner Change-24.87%
Ins Owners0.39%
Ins Owner Change0%
Market Cap5.26M
Revenue(TTM)N/A
Net Income(TTM)-3.52M
Analysts43.33
Price TargetN/A
Short Float %7.91%
Short Ratio6.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.12
P/tB 0.13
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0
BVpS6.41
TBVpS6.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.8%
ROE -8.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)2.56%
ROA(5y)-9%
ROE(3y)-1.51%
ROE(5y)-12.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.01
Quick Ratio 18.01
Altman-Z -0.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-152.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164.29%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-94.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.35%
OCF growth 3YN/A
OCF growth 5YN/A

PHARMACYTE BIOTECH INC / PMCB FAQ

What is the fundamental rating for PMCB stock?

ChartMill assigns a fundamental rating of 3 / 10 to PMCB.


What is the valuation status of PHARMACYTE BIOTECH INC (PMCB) stock?

ChartMill assigns a valuation rating of 0 / 10 to PHARMACYTE BIOTECH INC (PMCB). This can be considered as Overvalued.


How profitable is PHARMACYTE BIOTECH INC (PMCB) stock?

PHARMACYTE BIOTECH INC (PMCB) has a profitability rating of 2 / 10.